Mark A Morgan

No ORCID on file · 4 papers in corpus · active 1994-2025

Study types

  • article 2
  • other 2

Condition tags

  • endometriosis 3
other 2025
LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker
NPJ precision oncology ·doi:10.1038/s41698-025-00849-1

Long interspersed element 1 (LINE-1) retrotransposons are repetitive sequences that can move within the genome by an autonomous mechanism. To limit their mutagenic potential, benign cells restrict LINE-1 expression through molecular mechani…

other 2023
H2Bub1 loss is an early contributor to clear cell ovarian cancer progression
JCI insight ·doi:10.1172/jci.insight.164995

Epigenetic aberrations, including posttranslational modifications of core histones, are major contributors to cancer. Here, we define the status of histone H2B monoubiquitylation (H2Bub1) in clear cell ovarian carcinoma (CCOC), low-grade se…

article 2016
Post-Surgical Readmissions Among Women Undergoing Benign and Malignant Gynecologic Surgery [17]
·doi:10.1097/01.aog.0000483633.51771.52

INTRODUCTION: To compare 30 day postoperative readmission rates and risk factors for readmission between women following benign and malignant gynecologic surgery. METHODS: We identified patients following benign and malignant gynecologic su…

article 1994
Endometriosis and tamoxifen therapy
International Journal of Gynecology & Obstetrics ·doi:10.1016/0020-7292(94)90767-6

Tamoxifen is an estrogen antagonist/agonist often associated with antiestrogenic effects such as hot flushes and vaginal dryness in premenopausal women. Estrogenic side-effects, such as thromboembolic phenomena and endometrial proliferation…